Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Director departure
|
Juno Therapeutics, Inc. (JUNO)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
03/05/2018 |
SC 13D/A
| CELGENE CORP reports a 85.4% stake in JUNO THERAPEUTICS, INC. |
02/22/2018 |
SC 13D/A
| CELGENE CORP reports a 9.7% stake in JUNO THERAPEUTICS, INC. |
02/21/2018 |
SC 13D/A
| CELGENE CORP reports a 9.7% stake in JUNO THERAPEUTICS, INC. |
02/14/2018 |
SC 13D/A
| CELGENE CORP reports a 9.7% stake in JUNO THERAPEUTICS, INC. |
02/07/2018 |
SC 13D/A
| BRATTON DOUGLAS K reports a 4.7% stake in Juno Therapeutics, Inc. |
02/02/2018 |
SC 13D/A
| CELGENE CORP reports a 9.7% stake in JUNO THERAPEUTICS, INC. |
01/22/2018 |
SC 13D/A
| CELGENE CORP reports a 9.7% stake in Juno Therapeutics, Inc. |
11/08/2017 |
SC 13D/A
| BRATTON DOUGLAS K reports a 6.7% stake in Juno Therapeutics, Inc. |
09/26/2017 |
SC 13D/A
| Celgene Switzerland LLC reports a 9.7% stake in Juno Therapeutics, Inc. |
07/17/2017 |
SC 13D/A
| BRATTON DOUGLAS K reports a 8.8% stake in Juno Therapeutics, Inc. |
03/27/2017 |
SC 13D/A
| Celgene Switzerland LLC reports a 9.7% stake in Juno Therapeutics, Inc. |
03/29/2016 |
SC 13D/A
| Celgene Switzerland LLC reports a 9.7% stake in Juno Therapeutics, Inc. |
|
|